Skip to main content
. 2024 May 15;59(2):138–146. doi: 10.1097/MCG.0000000000002006

TABLE 3.

Patient Adherence to Current Off-Label Corticosteroid Treatments in Adolescents (Caregiver-Reported) and Adults (Self‑Reported) With EoE.

Survey question Adolescents* (n=98) Adults (n=103)
Over the past 7 days, did you [your child] at any time forget to take or choose not to take [insert name of treatment] to treat your [his/her] EoE? Please select all that apply.
 Yes, I [he/she] forgot to take my [his/her] treatment 37 (37.8) 40 (38.8)
 Yes, I [he/she] chose not to take my [his/her] treatment 9 (9.2) 16 (15.5)
 No, I [he/she] took my [his/her] treatment every day over the past 7 days 55 (56.1) 53 (51.5)
Over the past 7 days, how many days did you [your child] forget or choose not to take your [his/her] treatment?
 n 43 50
 Number of days, mean (SD) 2.0 (1.5) 2.3 (1.6)
 Proportion of days, % 28.6 32.9
Why did you [your child] choose not to take [insert name of treatment] to treat your [his/her] EoE over the past 7 days? Please select all that apply.
 n 9 16
 [My child thinks the] The medicine tastes bad 5 (55.6) 0 (0.0)
 I [My child] felt depressed/overwhelmed 4 (44.4) 5 (31.3)
 My [His/her] EoE symptoms have not been bothersome 3 (33.3) 4 (25.0)
 I [He/she] felt okay, so I did not think it was necessary to take the medicine daily 3 (33.3) 3 (18.8)
 I have difficulty taking it [giving it to my child] at the specific time I am [he/she is] supposed to take it 1 (11.1) 5 (31.3)
 I [He/she] experienced side effects from the medicine 2 (22.2) 3 (18.8)
 I [He/she] had too many other pills/medications to take 1 (11.1) 3 (18.8)
 It is not effective at controlling my [my child’s] EoE symptoms 0 (0.0) 2 (12.5)
 The medicine is expensive 0 (0.0) 2 (12.5)
 The medicine is difficult or inconvenient to get from the pharmacy in a timely manner 0 (0.0) 2 (12.5)
 I did not have the medicine available (eg, away from home, on vacation) 0 (0.0) 2 (12.5)
 I [My child] just needed a break 1 (11.1) 2 (12.5)
 Other 3 (33.3) 3 (18.8)

Data are presented as n (%) unless otherwise specified. Corticosteroid treatment adherence was assessed using the MGL-4; data presented are responses to items from the MGL-4.

*

Minor changes to the wording of the MGL-4 were made for the adolescent survey to apply to a caregiver’s perspective; all differences in wording are shown in square brackets.

Included only participants who reported that they/their child chose not to take the medication.

EoE indicates eosinophilic esophagitis; MGL-4, 4-item Morisky Green Levine Medication Adherence Scale.